DE69324025D1 - Transdermal treatment of hives with OPTICALLY PURE (+) - CETIRIZINE - Google Patents

Transdermal treatment of hives with OPTICALLY PURE (+) - CETIRIZINE

Info

Publication number
DE69324025D1
DE69324025D1 DE69324025T DE69324025T DE69324025D1 DE 69324025 D1 DE69324025 D1 DE 69324025D1 DE 69324025 T DE69324025 T DE 69324025T DE 69324025 T DE69324025 T DE 69324025T DE 69324025 D1 DE69324025 D1 DE 69324025D1
Authority
DE
Germany
Prior art keywords
cetirizine
optically pure
treatment
hives
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69324025T
Other languages
German (de)
Other versions
DE69324025T2 (en
Inventor
Nancy M Gray
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Application granted granted Critical
Publication of DE69324025D1 publication Critical patent/DE69324025D1/en
Publication of DE69324025T2 publication Critical patent/DE69324025T2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Methods and compositions are disclosed utilizing optically pure (+) cetirizine for the treatment of seasonal and perennial allergic rhinitis in humans while avoiding the concomitant liability of adverse effects associated with the racemic mixture of cetirizine. The optically pure (+) isomer is also useful for the treatment of allergic asthma and chronic and physical urticaria. (+) cetirizine is an inhibitor of eosinophil chemotaxis and is therefore useful in the treatment of other conditions related to eosinophilia such as allergic asthma, seasonal allergic rhinitis, atopic dermatitis, some parasitic diseases, some chronic obstructive lung diseases and certain gastrointestinal and genitourinary disorders.
DE69324025T 1992-09-24 1993-09-22 Transdermal treatment of hives with OPTICALLY PURE (+) - CETIRIZINE Expired - Fee Related DE69324025T2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95091092A 1992-09-24 1992-09-24
PCT/US1993/008999 WO1994006430A1 (en) 1992-09-24 1993-09-22 Methods and compositions for treating allergic disorders using optically pure (+) cetirizine

Publications (2)

Publication Number Publication Date
DE69324025D1 true DE69324025D1 (en) 1999-04-22
DE69324025T2 DE69324025T2 (en) 1999-07-15

Family

ID=25491013

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69324025T Expired - Fee Related DE69324025T2 (en) 1992-09-24 1993-09-22 Transdermal treatment of hives with OPTICALLY PURE (+) - CETIRIZINE

Country Status (11)

Country Link
US (1) US5627183A (en)
EP (2) EP0885611A3 (en)
JP (1) JPH08501562A (en)
AT (1) ATE177636T1 (en)
AU (1) AU5136193A (en)
CA (1) CA2145413A1 (en)
DE (1) DE69324025T2 (en)
DK (1) DK0661975T3 (en)
ES (1) ES2128556T3 (en)
GR (1) GR3029927T3 (en)
WO (1) WO1994006430A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831066A (en) 1988-12-22 1998-11-03 The Trustees Of The University Of Pennsylvania Regulation of bcl-2 gene expression
ATE170749T1 (en) * 1992-09-24 1998-09-15 Sepracor Inc USE OF (-)CETIRIZINE FOR THE TREATMENT OF ALLERGIC RHINITIS AND AND ASTHMA
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine
US6469009B1 (en) 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
IN188720B (en) * 1997-11-06 2002-11-02 Panacea Biotec Ltd
US6432961B1 (en) 1998-08-18 2002-08-13 Ucb S.A. Method for preventing the onset of asthma
US6762347B1 (en) * 1999-07-12 2004-07-13 James Giovannoni NOR gene compositions and methods for use thereof
KR20020068385A (en) * 1999-12-28 2002-08-27 데이고꾸세이약꾸가부시끼가이샤 Antipruritic agents for external use
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US6596686B2 (en) 2001-03-12 2003-07-22 International Flavors & Fragrances Inc. Use of dihydropyrans as fragrance Material
WO2004069338A1 (en) * 2003-01-31 2004-08-19 Schering Corporation Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions
GB2403655A (en) * 2003-07-11 2005-01-12 Cipla Ltd Combined pharmaceutical product comprising a beta-2 adrenoreceptor agonist & an antihistamine for treatment of respiratory diseases such as asthma
WO2005077371A1 (en) * 2004-02-12 2005-08-25 Ucb Farchim Sa Use of levocetirizine for the preparation of a drug
US8513259B2 (en) 2009-07-03 2013-08-20 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
US11253513B2 (en) 2019-10-07 2022-02-22 Jdp Therapeutics Llc Dosing regimen for injectable cetirizine

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO155805C (en) * 1981-02-06 1987-06-10 Ucb Sa ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (4- (DIPHENYLMETHYL) -1-PIPERAZINYL) -ACDIC ACIDS AND THEIR AMIDS AND NON-TOXIC SALTS.
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
GB8827390D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
GB8827391D0 (en) * 1988-11-23 1988-12-29 Ucb Sa Process for preparation of 2-(2-(4-((4-chlorophenyl)phenylmethyl)-1-pipera-zinyl)ethoxy)-acetic acid & its dihydrochloride
ATE170749T1 (en) * 1992-09-24 1998-09-15 Sepracor Inc USE OF (-)CETIRIZINE FOR THE TREATMENT OF ALLERGIC RHINITIS AND AND ASTHMA
GB9305282D0 (en) * 1993-03-15 1993-05-05 Ucb Sa Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulphonyl)piperazine

Also Published As

Publication number Publication date
ATE177636T1 (en) 1999-04-15
EP0885611A3 (en) 1999-01-07
WO1994006430A1 (en) 1994-03-31
DK0661975T3 (en) 1999-09-27
EP0661975B1 (en) 1999-03-17
DE69324025T2 (en) 1999-07-15
JPH08501562A (en) 1996-02-20
EP0661975A1 (en) 1995-07-12
AU5136193A (en) 1994-04-12
GR3029927T3 (en) 1999-07-30
US5627183A (en) 1997-05-06
EP0885611A2 (en) 1998-12-23
CA2145413A1 (en) 1994-03-31
ES2128556T3 (en) 1999-05-16

Similar Documents

Publication Publication Date Title
ATE170749T1 (en) USE OF (-)CETIRIZINE FOR THE TREATMENT OF ALLERGIC RHINITIS AND AND ASTHMA
DE69324025T2 (en) Transdermal treatment of hives with OPTICALLY PURE (+) - CETIRIZINE
CA2161256A1 (en) Methods and compositions for treating gastric disorders using optically pure (-) pantoprazole
ES2171543T3 (en) TOPICALLY ADMINISTRABLE COMPOSITIONS CONTAINING DERIVATIVES OF 3-BENZOYL PHENYLACETIC ACID FOR THE TREATMENT OF OPTALMIC INFLAMMATORY DISORDERS.
BG103725A (en) Nicotineamide derivatives
DK0713701T3 (en) 2-Bromelatonin for the treatment of sleep disorders
FI904035A0 (en) Process for Preparation of Therapeutically Active 4-Substituted 17 - (Cyclopropyloxy) Androst-5-ene Derivatives Useful as C17-20 Lyase Inhibitors
DK0379145T3 (en) Substituted quinoline carboxylic acids
DE60129221D1 (en) USE OF ALPHA-MSH AND EPO FOR THE MANUFACTURE OF A MEDICAMENT FOR THE PROPHYLAXIS OR TREATMENT OF DISEASES CAUSED BY ISCHEMIC CONDITIONS
NO20052560L (en) Crystalline fumarate salts of N- [1-azabicyclo (2.2.2) oct-3yl] furo (2,3-C) pyridinyl-5-carboxamide and compositions and preparations thereof.
ATE101147T1 (en) PHARMACEUTICALLY USEABLE POLYMORPH MODIFICATION OF BUSPIRON.
ES2116343T3 (en) QUINUCLIDINE ESTERS, PROCEDURE AND INTERMEDIATES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
ES2181702T3 (en) MELATONIN DERIVATIVES FOR USE IN THE TREATMENT OF ILLNESS IS SLEEP.
FI971193A (en) Therapeutically useful quinoxaline derivatives
IS3961A (en) Indole derivatives, their method of manufacture and use as pharmaceuticals
FI851617L (en) TRIAZOLOPYRIMIDINDERIVAT.
FR2653999B1 (en)
MX9710257A (en) Novel azepanes and their ring homologues for therapy and prophylaxis of protein kinase mediated diseases.
DE502004011353D1 (en) Process for the distillation of a mixture of isomeric diisocyanatodiphenylmethanes

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee